Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Year: 2024
Type: conference-abstract
Source: Blood
Institutions: Hospital Universitario 12 De Octubre, Yale Cancer Center, Yale University, Janssen (Belgium), Johnson & Johnson (United States), Legend Biotech (United States), Japanese Red Cross Medical Center, Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, Memorial Sloan Kettering Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405038693